Related references
Note: Only part of the references are listed.A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells
Melissa A. Gray et al.
CHEMBIOCHEM (2016)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Trastuzumab in the Treatment of Breast Cancer
Sofia Maximiano et al.
BIODRUGS (2016)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside
Gabriela Kramer-Marek et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET
Ganesan Vaidyanathan et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
Geraldine Gebhart et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
18F-nanobody for PET imaging of HER2 overexpressing tumors
Catarina Xavier et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients
Brigitte Rack et al.
ONCOLOGY (2016)
N-Succinimidyl 3-((4-(4-[F-18] fluorobutyl)-1H-1,2,3-triazol-1 yl) methyl)-5-(guanidinomethyl)benzoate ([F-18] SFBTMGMB): a residualizing label for F-18-labeling of internalizing biomolecules
Ganesan Vaidyanathan et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
The assessment of HER2 status in breast cancer: the past, the present, and the future
Hiroaki Nitta et al.
PATHOLOGY INTERNATIONAL (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
89Zr-Labeled Versus 124I-Labeled HER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo
C. T. Mendler et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Nanobody-based cancer therapy of solid tumors
Marta Kijanka et al.
NANOMEDICINE (2015)
Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases
Deepak Kanojia et al.
STEM CELLS (2015)
Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
Sebastian Trousil et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation In Vivo
Teng Ma et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling
Marek Pruszynski et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
M. Lemaire et al.
LEUKEMIA (2014)
N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization
Jaeyeon Choi et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Nanobody-based products as research and diagnostic tools
Thomas De Meyer et al.
TRENDS IN BIOTECHNOLOGY (2014)
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
Matthias D'Huyvetter et al.
THERANOSTICS (2014)
Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions
Duriye S. Karagoz Ozen et al.
ONCOLOGY RESEARCH AND TREATMENT (2014)
Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography
Alejandro Sanchez-Crespo
APPLIED RADIATION AND ISOTOPES (2013)
Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain
Sashikanth Banappagari et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer
Catarina Xavier et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
Marek Pruszynski et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators
Matthias D'Huyvetter et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2012)
Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model
Gabriela Kramer-Marek et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging
Tove Olafsen et al.
TUMOR BIOLOGY (2012)
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer
Ilse Vaneycken et al.
FASEB JOURNAL (2011)
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
Gloria Fuentes et al.
BREAST CANCER RESEARCH (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies
Johan Rockberg et al.
MOLECULAR ONCOLOGY (2009)
Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I] iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides
Ganesan Vaidyanathan et al.
NATURE PROTOCOLS (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1
Zhenming Yu et al.
MOLECULAR CARCINOGENESIS (2006)
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
T Olafsen et al.
CANCER RESEARCH (2005)